Immunomedics Inc. (IMMU) stops accent study due to efficacy
Immunomedics Inc. (IMMU) currently trades at $19.25 and has grown by 104.68% today. IMMU announced today that its Phase 3 confirmatory ASCENT study will be halted due to compelling evidence of efficacy. This decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC), during its recent routine review of the ASCENT study. “It is my distinct honor to have served as Chairperson of the independent DSMC for this important study,” said remarked Julie R. Gralow, MD, Jill Bennett Endowed Professor of Breast Cancer, University of Washington School of Medicine.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article. The high forecast for Immunomedics Inc. is $35.00 and the low is $5.00. Notably, the company’s market cap is $4.06 billion with a 52 week high of $22.22 and a 52 week low of $8.80. IMMU has gained $9.84 from the previous closing price of $9.40. IMMU has changed in price by +0.39 per share in the last 12 months.